188 related articles for article (PubMed ID: 12438394)
1. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the znuA virulence factor attenuates Actinobacillus pleuropneumoniae and confers protection against homologous or heterologous strain challenge.
Yuan F; Liao Y; You W; Liu Z; Tan Y; Zheng C; BinWang ; Zhou D; Tian Y; Bei W
Vet Microbiol; 2014 Dec; 174(3-4):531-539. PubMed ID: 25465668
[TBL] [Abstract][Full Text] [Related]
3. The live attenuated Actinobacillus pleuropneumoniae triple-deletion mutant ΔapxIC ΔapxIIC ΔapxIV-ORF1 strain, SLW05, Immunizes pigs against lethal challenge with Haemophilus parasuis.
Fu S; Ou J; Zhang M; Xu J; Liu H; Liu J; Yuan F; Chen H; Bei W
Clin Vaccine Immunol; 2013 Feb; 20(2):134-9. PubMed ID: 23220998
[TBL] [Abstract][Full Text] [Related]
4. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
Liu J; Chen Y; Hu L; Bei W; Chen H
Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
[TBL] [Abstract][Full Text] [Related]
5. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker.
Bei W; He Q; Yan L; Fang L; Tan Y; Xiao S; Zhou R; Jin M; Guo A; Lv J; Huang H; Chen H
FEMS Microbiol Lett; 2005 Feb; 243(1):21-7. PubMed ID: 15667996
[TBL] [Abstract][Full Text] [Related]
7. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
[TBL] [Abstract][Full Text] [Related]
8. Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals.
Maas A; Jacobsen ID; Meens J; Gerlach GF
Infect Immun; 2006 Jul; 74(7):4124-32. PubMed ID: 16790786
[TBL] [Abstract][Full Text] [Related]
9. Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.
Xie F; Li G; Zhou L; Zhang Y; Cui N; Liu S; Wang C
BMC Vet Res; 2017 Jan; 13(1):14. PubMed ID: 28061786
[TBL] [Abstract][Full Text] [Related]
10. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
[TBL] [Abstract][Full Text] [Related]
12. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.
Liu J; Chen X; Lin L; Tan C; Chen Y; Guo Y; Jin M; Guo A; Bei W; Chen H
Vaccine; 2007 Nov; 25(44):7696-705. PubMed ID: 17767980
[TBL] [Abstract][Full Text] [Related]
13. Cross-protection between Actinobacillus pleuropneumoniae biotypes-serotypes in pigs.
Haesebrouk F; Van de Kerkhof A; Dom P; Chiers K; Ducatelle R
Vet Microbiol; 1996 Oct; 52(3-4):277-84. PubMed ID: 8972053
[TBL] [Abstract][Full Text] [Related]
14. Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies.
Ramjeet M; Deslandes V; Gouré J; Jacques M
Anim Health Res Rev; 2008 Jun; 9(1):25-45. PubMed ID: 18346296
[TBL] [Abstract][Full Text] [Related]
15. Both transferrin binding proteins are virulence factors in Actinobacillus pleuropneumoniae serotype 7 infection.
Baltes N; Hennig-Pauka I; Gerlach GF
FEMS Microbiol Lett; 2002 Apr; 209(2):283-7. PubMed ID: 12007819
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
[TBL] [Abstract][Full Text] [Related]
17. Construction and immunogenicity of a ∆apxIC/ompP2 mutant of Actinobacillus pleuropneumoniae and Haemophilus parasuis.
Liu Q; Gong Y; Cao Y; Wen X; Huang X; Yan Q; Huang Y; Cao S
Onderstepoort J Vet Res; 2013 Mar; 80(1):519. PubMed ID: 23718128
[TBL] [Abstract][Full Text] [Related]
18. Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs.
Wu HC; Yeh PH; Hsueh KJ; Yang WJ; Chu CY
J Appl Microbiol; 2018 Jun; 124(6):1366-1376. PubMed ID: 29431246
[TBL] [Abstract][Full Text] [Related]
19. A genetically-defined riboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine.
Fuller TE; Thacker BJ; Duran CO; Mulks MH
Vaccine; 2000 Jun; 18(25):2867-77. PubMed ID: 10812230
[TBL] [Abstract][Full Text] [Related]
20. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
Loera-Muro A; Angulo C
Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
